Payment overview · 2025
General Payments
$150.00
1 reported records · 1 companies
Healthcare provider profile · identity verified
Jasmine Jones Hohl
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · SALT LAKE CITY, UT · NPI 1700335395
Verified facts
What the public records show
CMS Open Payments records show Jasmine Jones Hohl received $150.00 in general payments during 2025 across 1 reported records.
H2-Pharma, LLC accounted for 100.0% of that reported general-payment amount.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| H2-Pharma, LLC | Unresolved — no canonical attribution shown | $150.00 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Honoraria | $150.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Olanzapine | Olanzapine | 487 | 49 |
| Aripiprazole | Aripiprazole | 391 | 47 |
| Quetiapine Fumarate | Quetiapine Fumarate | 383 | 39 |
| Lamotrigine | Lamotrigine | 329 | 45 |
| Trazodone Hcl | Trazodone Hcl | 310 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 275 | 30 |
| Benztropine Mesylate | Benztropine Mesylate | 270 | 28 |
| Buspirone Hcl | Buspirone Hcl | 266 | 33 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 247 | 40 |
| Divalproex Sodium Er | Divalproex Sodium | 240 | 22 |
| Prazosin Hcl | Prazosin Hcl | 229 | 19 |
| Sertraline Hcl | Sertraline Hcl | 192 | 20 |
| Risperidone | Risperidone | 183 | 21 |
| Propranolol Hcl | Propranolol Hcl | 177 | 26 |
| Divalproex Sodium | Divalproex Sodium | 174 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 174 | 20 |
| Invega Sustenna | Paliperidone Palmitate | 165 | 15 |
| Mirtazapine | Mirtazapine | 144 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 134 | 13 |
| Gabapentin | Gabapentin | 133 | 16 |
| Haloperidol | Haloperidol | 126 | 13 |
| Vraylar | Cariprazine Hcl | 123 | 13 |
| Haloperidol Decanoate | Haloperidol Decanoate | 120 | suppressed |
| Abilify Maintena | Aripiprazole | 112 | 12 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 107 | 12 |
| Metformin Hcl | Metformin Hcl | 104 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 84 | 11 |
| Omeprazole | Omeprazole | 84 | suppressed |
| Bupropion Xl | Bupropion Hcl | 82 | 13 |
| Lurasidone Hcl | Lurasidone Hcl | 77 | 13 |
| Topiramate | Topiramate | 74 | 13 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 70 | suppressed |
| Famotidine | Famotidine | 67 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 67 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 67 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 57 | suppressed |
| Belsomra | Suvorexant | 56 | suppressed |
| Lorazepam | Lorazepam | 56 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 55 | suppressed |
| Clonazepam | Clonazepam | 53 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 51 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 47 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 44 | suppressed |
| Dayvigo | Lemborexant | 43 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 43 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 40 | suppressed |
| Simvastatin | Simvastatin | 39 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 38 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 36 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 36 | suppressed |
| Lisinopril | Lisinopril | 36 | suppressed |
| Olanzapine Odt | Olanzapine | 34 | suppressed |
| Eszopiclone | Eszopiclone | 33 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 32 | suppressed |
| Losartan Potassium | Losartan Potassium | 30 | suppressed |
| Perphenazine | Perphenazine | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 28 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 26 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Invega Trinza | Paliperidone Palmitate | 26 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 26 | suppressed |
| Rexulti | Brexpiprazole | 26 | suppressed |
| Zaleplon | Zaleplon | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Paliperidone Er | Paliperidone | 25 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 25 | suppressed |
| Amantadine | Amantadine Hcl | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Austedo | Deutetrabenazine | 23 | suppressed |
| Lamotrigine Er | Lamotrigine | 22 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 18 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 18 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 15 | suppressed |
| Clozapine | Clozapine | 14 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Abilify | Aripiprazole | 13 | suppressed |
| Aristada | Aripiprazole Lauroxil | 13 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Lamictal | Lamotrigine | 13 | suppressed |
| Potassium Chloride | Potassium Chloride | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Effexor Xr | Venlafaxine Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Furosemide | Furosemide | 11 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $150.00 · 1 records | H2-Pharma, LLC | — | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error